A novel series of
fluorophenyl-based thiazoles was synthesized
following the Hanztsch method. All of the compounds were initially
verified with physical parameters (color, melting point, retardation
factor (R
f)), which were further confirmed
by several spectroscopic methods, including ultraviolet–visible
(UV–visible), Fourier-transform infrared (FTIR), 1H, 13C, 19F NMR, and high-resolution mass spectrometry
(HRMS). The binding interactions of all compounds were studied using
a molecular docking simulation approach. Furthermore, each compound
was evaluated for its alpha(α)-amylase, antiglycation, and antioxidant
potentials. The biocompatibility of all compounds was checked with
an in vitro hemolytic assay. All synthesized scaffolds
were found biocompatible with minimal lysis of human erythrocytes
as compared to the standard Triton X-100. Among the tested compounds,
the analogue 3h (IC50 = 5.14 ± 0.03 μM)
was found to be a highly potent candidate against α-amylase
as compared to the standard (acarbose, IC50 = 5.55 ±
0.06 μM). The compounds 3d, 3f, 3i, and 3k exhibited excellent antiglycation
inhibition potential with their IC50 values far less than
the standard amino guanidine (IC50 = 0.403 ± 0.001
mg/mL). The antidiabetic potential was further supported by docking
studies. Docking studies revealed that all synthesized compounds exhibited
various interactions along enzyme active sites (pi–pi, H-bonding,
van der Waals) with varied binding energies.